Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children - Results of a multicenter study

Haematologica

Volumn 92, Issue 7, 2007, Pages 982-985

  Kurnik, Karin ^a   Kreuz, Wolfhart ^b   Horneff, Sylvia ^c   Düring, Christine ^d   Schobess, Rosemarie ^c   Bidlingmaier, Christoph ^a   Ettingshausen, Carmen Escuriola ^b   Krümpel, Anne ^d   Bogdanova, Nadia ^e   Nowak Göttl, Ulrike ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Pediatric PUPs; Pettersson score; Severe hemophilia A; Synovitis; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5; PROTHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN;

ADOLESCENT; ADULT; ARTHROPATHY; ARTICLE; BLEEDING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HEMOPHILIA A; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; RISK FACTOR; SCHOOL CHILD; SCORING SYSTEM; THROMBOPHILIA; CHILD; CLINICAL TRIAL; GENETICS; MULTICENTER STUDY; POINT MUTATION; RETROSPECTIVE STUDY;

CHILD; FACTOR V; HEMOPHILIA A; HEMORRHAGE; HUMANS; POINT MUTATION; PROTHROMBIN; RETROSPECTIVE STUDIES; THROMBOPHILIA;

EID: 34548791196     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11161     Document Type: Article

References (20)

1. Oldenburg J, Schröder J, Schmitt C, Brackmann HH, Schwab R. Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigates the severe haemophilia A phenotype. Thromb Haemost 1998;79:452-3.
2. Nichols WC, Amano K, Cacheris PM, Figueiredo MS, Michaelides K, Schwaab R, et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88:1183-7.
3. Tizzano EF, Soria JM, Coll M, Guzman B, Comet M, Altisent C, et al. The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors. Haematologica 2002;87:279-85.
4. Escuriola Ettingshausen C, Halimeh S, Kurnik K, Schobess R, Wermes C, Junker R, et al. Hemophilia phenotype is dependent on the presence of prothrombotic risk factors. A multicenter cohort study. Thromb Haemost 2001; 85:218-20.
5. Schlachterman A, Schuettrumpf J, Liu JH, Furlan Freguia C, Toso R, Poncz M, et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost 2005; 3:2730-7.
6. Veer van't C, Golden NJ, Kalafatis M, Simioni P, Bertina R, Mann G. An in vitro analysis of the combination of hemophilia A and factor V Leiden. Blood 1997;90:3067-72.
7. Kreuz W, Escuriola Ettingshausen C, Funk M, Pons S, Schmidt H, Kornhuber B. Prevention of joint damage in hemophiliac children with early prophylaxis. Orthopäde 1999;28:341-6.
8. Ljung R. Paediatric care of the child with haemophilia. Haemophilia 2002; 8:178-82.
9. Pettersson H, Nilsson IM, Hedner U, Norehn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paed Scand 1981; 70:565-70.
10. Nuss R, Kilcoyne RF, Geraghty S, Shroyer AL, Rosky JW, Mawhinney S, et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 2000; 6:162-9.
11. Kern M, Blanchette V, Stain AM, Einarson TR, Feldman BM. Clinical and cost implications of target joints in Canadian boys with severe hemophilia. J Pediatr 2004;145:628-34.
12. Junker R, Koch HG, Auberger K, Münchow N, Ehrenforth S, Nowak-Götd U. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999;19:2568-72.
13. Bogdanova N, Markoff A, Pollmann H, Nowak-Göttl U, Eisert R et al. Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A. Hum Mutat 2005;26:249-54.
14. Lee DH, Walker IR, Teitel J, Poon MC, Ritchie B, Akabutu J, et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000;83:387-91.
15. Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiologica 2002; 43:528-32.
16. Van den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, et al. Long-term outcome in individualized prophylactic treatment of children with severe haemophilia. Br. J Haematol 2001;112:561-5.
17. Fischer K, Astermark J, van der Bom JG, Ljung R, Berntorp E, Grobbee DE, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002;8:753-60.
18. Carlsson KS, Höjgard S, Glomstein A, Lethagen S, Schulman S, Tengborn L, et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003;9:555-66.
19. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, Grobbee DE, et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001;7:446-52.
20. Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis. Thromb Haemost 1995;74:1255-8.